全文获取类型
收费全文 | 105927篇 |
免费 | 5702篇 |
国内免费 | 280篇 |
专业分类
耳鼻咽喉 | 1220篇 |
儿科学 | 2498篇 |
妇产科学 | 2201篇 |
基础医学 | 14613篇 |
口腔科学 | 5331篇 |
临床医学 | 8330篇 |
内科学 | 24652篇 |
皮肤病学 | 2360篇 |
神经病学 | 9058篇 |
特种医学 | 2460篇 |
外国民族医学 | 1篇 |
外科学 | 13310篇 |
综合类 | 709篇 |
一般理论 | 40篇 |
预防医学 | 10062篇 |
眼科学 | 1794篇 |
药学 | 7339篇 |
中国医学 | 557篇 |
肿瘤学 | 5374篇 |
出版年
2023年 | 726篇 |
2022年 | 910篇 |
2021年 | 2219篇 |
2020年 | 1434篇 |
2019年 | 2162篇 |
2018年 | 3353篇 |
2017年 | 2260篇 |
2016年 | 2349篇 |
2015年 | 3018篇 |
2014年 | 3382篇 |
2013年 | 4538篇 |
2012年 | 8944篇 |
2011年 | 9326篇 |
2010年 | 4376篇 |
2009年 | 3243篇 |
2008年 | 7485篇 |
2007年 | 7630篇 |
2006年 | 7451篇 |
2005年 | 7001篇 |
2004年 | 6333篇 |
2003年 | 5761篇 |
2002年 | 5426篇 |
2001年 | 2153篇 |
2000年 | 2705篇 |
1999年 | 1524篇 |
1998年 | 437篇 |
1997年 | 312篇 |
1996年 | 315篇 |
1995年 | 289篇 |
1994年 | 232篇 |
1993年 | 215篇 |
1992年 | 363篇 |
1991年 | 338篇 |
1990年 | 278篇 |
1989年 | 281篇 |
1988年 | 239篇 |
1987年 | 191篇 |
1986年 | 195篇 |
1985年 | 206篇 |
1984年 | 215篇 |
1983年 | 154篇 |
1982年 | 141篇 |
1981年 | 126篇 |
1980年 | 122篇 |
1979年 | 130篇 |
1978年 | 120篇 |
1977年 | 87篇 |
1975年 | 83篇 |
1974年 | 106篇 |
1973年 | 93篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
991.
Vicente Valentín Maganto Carlos Camps Herrero Joan Carulla Torrent Javier Cassinello Espinosa Javier Dorta Delgado Carlos Jara Sánchez José Andrés Moreno Nogueira 《Clinical & translational oncology》2005,7(5):205-212
INTRODUCTION: Oral trans-mucosal fentanyl citrate (OTFC) is the one drug specifically developed for the management of breakthrough pain. This study assesses the long-term safety and efficacy of OTFC standard clinical conditions. Patients and methods. Six-month observational study performed on cancer patients with episodes of breakthrough pain. Safety was assessed by recording the advent of adverse events and efficacy by the evaluating the intensity of breakthrough pain. RESULTS: 174 cancer patients were recruited into the study. All adverse reactions reported were mild or moderate. OTFC was significantly faster (time to the commencement of pain relief: 12.7 +/- 11.4 vs 32.7 +/- 18.4 minutes; p < 0.001) and potent (post-treatment pain intensity: 3.4 +/- 1.5 vs 4.3 +/- 1.5; p < 0.001) than the previously-used drugs. CONCLUSIONS: This observational study confirms the good safety profile of OTFC as well as its effectiveness over long-term period treatment of breakthrough pain. 相似文献
992.
Josée Savard Sébastien Simard Hans Ivers Charles M Morin 《Journal of clinical oncology》2005,23(25):6083-6096
PURPOSE: Chronic insomnia is highly prevalent in cancer patients. Cognitive-behavioral therapy (CBT) is considered the treatment of choice for chronic primary insomnia. However, no randomized controlled study has been conducted on its efficacy for insomnia secondary to cancer. Using a randomized controlled design, this study conducted among breast cancer survivors evaluated the effect of CBT on sleep, assessed both subjectively and objectively, and on hypnotic medication use, psychological distress, and quality of life. PATIENTS AND METHODS: Fifty-seven women with insomnia caused or aggravated by breast cancer were randomly assigned to CBT (n = 27) or a waiting-list control condition (n = 30). The treatment consisted of eight weekly sessions administered in a group and combined the use of stimulus control, sleep restriction, cognitive therapy, sleep hygiene, and fatigue management. Follow-up evaluations were carried out 3, 6, and 12 months after the treatment. RESULTS: Participants who received the insomnia treatment had significantly better subjective sleep indices (daily sleep diary, Insomnia Severity Index), a lower frequency of medicated nights, lower levels of depression and anxiety, and greater global quality of life at post-treatment compared with participants of the control group after their waiting period. Results were more equivocal on polysomnographic indices. Therapeutic effects were well maintained up to 12 months after the intervention and generally were clinically significant. CONCLUSION: This study supports the efficacy of CBT for insomnia secondary to breast cancer. 相似文献
993.
Josée Savard Sébastien Simard Hans Ivers Charles M Morin 《Journal of clinical oncology》2005,23(25):6097-6106
PURPOSE: Cross-sectional studies suggest that clinical insomnia is associated with immune downregulation. However, there is a definite need for experimental studies on this question. The goal of this randomized controlled study was to assess the effect of an 8-week cognitive-behavioral therapy (CBT) for chronic insomnia on immune functioning of breast cancer survivors. Previous analyses of this study showed that CBT was associated with improved sleep and quality of life, and reduced psychological distress. PATIENTS AND METHODS: Fifty-seven women with chronic insomnia secondary to breast cancer were randomly assigned to CBT (n = 27) or to a waiting-list control condition (WLC; n = 30). Peripheral-blood samples were taken at baseline and post-treatment (and postwaiting for WLC patients), as well as at 3-, 6-, and 12-month follow-up for immune measures, including enumeration of blood cell counts (ie, WBCs, monocytes, lymphocytes, CD3+, CD4+, CD8+, and CD16+/CD56+) and cytokine production (ie, interleukin-1-beta [IL-1beta] and interferon gamma [IFN-gamma]). RESULTS: Patients treated with CBT had higher secretion of IFN-gamma and lower increase of lymphocytes at post-treatment compared with control patients. Pooled data from both treated groups indicated significantly increased levels of IFN-gamma and IL-1beta from pre- to post-treatment. In addition, significant changes in WBCs, lymphocytes, and IFN-gamma were found at follow-up compared with post-treatment. CONCLUSION: This study provides some support to the hypothesis of a causal relationship between clinical insomnia and immune functioning. Future studies are needed to investigate the clinical impact of such immune alterations. 相似文献
994.
Carlos García-Girón Andrés García Palomo Carmen Alonso López Ángel León Carbonero Miguel Méndez Urena Encarna Adróver Cebrián Ramón Barceló Galíndez Mónica Arroyo Yustos José Álvarez Gallego 《Clinical & translational oncology》2005,7(6):244-249
Introduction This phase II study investigated the anti-tumour activity and toxicity of CPT-11 (250 mg/m2 i.v. infusion over 60 minutes)
administered every 2 weeks as second-line chemotherapy in patients with advanced colorectal cancer (CRC).
Material and methods Patients (n=63) with histology diagnosis of advanced CRC and proven resistance to previous fluoropyrimidine therapy were enrolled.
Results A total of 510 CPT-11 cycles were administered, with a mean of 8 cycles per patient (range: 1–32). The median relative dose
intensity was 93%. Partial response (PR) was obtained in 11 patients (17.5%; 95%CI: 8.1%–26.7%) and 29 patients (46.0%) showed
stable disease (clinical benefit of 63.5%). The median duration of response was 6.8 months (95%CI: 6.1–7.5 months), median
survival was 8.8 months (95%CI: 6.3–11.5 months) and median time to disease progression was 4.5 months (95%CI: 3.9–5.0 months).
Overall, this schedule of CPT-11 chemotherapy was well tolerated by the patient. Neutropenia was the most frequent grade 3/4
haematological toxicity (20.6% of patients and 4.1% of cycles). Neutropenia with concurrent fever or infection occurred in
7 patients (11.1%). Late onset diarrhoea was the most frequent grade 3/4 non-haematological toxicity (19.0% of patients and
2.3% of cycles). Other, lower-incidence, toxicities were anaemia, fever, infection, mucositis, nausea and vomiting. There
were no toxic deaths.
Conclusions We found that CPT-11, administered as 250 mg/m2 i.v. infusion over 60 minutes every 2 weeks, was active and well tolerated schedule in the second-line chemotherapy of advanced
CRC patients. This bi-weekly scheme could be used as an alternative to the weekly or the every-three-week schedule as well
as in combined therapies with other chemotherapeutic agents for the treatment of advanced, metastatic, CRC. 相似文献
995.
Sonia Maciá Escalante Carmen Guillén Ponce Ma José Molina Garrido Ma José Martínez Ortiz Inmaculada Ballester Navarro Alfredo Carrato Mena 《Clinical & translational oncology》2005,7(9):414-416
Prognosis in prostate cancer is determined, in greater part, by the presence of metastases. Bone metastases can occur in any part of the skeleton even, for example, at the base of the skull. We present a case of a 78 year old male who, in December 2001, presented with paralysis of the third cranial nerve. The NMR and CAT scans were normal and circulating levels of PSA were elevated. He was referred to the Urology Service where the treatment guidelines included complete androgen block. Subsequently, he developed retro-orbital pain, divergent strabismus and palpebral ptosis. CAT and NMR indicated a soft tissue mass at the sphenoid level. Treatment was Gamma Knife Radio-surgery. Since August 2004, in conjunction with the latest rise in PSA, the patient's general status deteriorated considerably and he was referred to the Oncology Service. there was an increase in the paralysis of the third, fourth and sixth cranial nerve (complete left ophthalmoplegia) and left-central facial paralysis. Metastases from prostate cancer can be disseminated via the lymphatic or the blood system. Currently, there are more metastases from large-size tumours. Metastases are critical in prostate cancer because of their adverse effect on the patient's survival. Measurements of circulating levels of prostate specific antigen and prostate acid phosphatase are very useful in the clinical diagnosis of the primary tumour, or its metastases. 相似文献
996.
Ana Lucas Calduch María Dolores Arnaiz Fernández Sol San José Maderuelo Valentí Navarro Pérez Gala Serrano Bermúdez Ana Montes Borinaga Felipe Cardenal Alemany Branislav Jeremic Ferran Guedea Edo 《Clinical & translational oncology》2005,7(7):314-320
Purpose We retrospectively reviewed our institution’s database to investigate the outcome and impact of combined radiochemotherapy
(RT/CT; concomitant or in sequence) in localised small-cell lung cancer (L-SCLC).
Material and methods Between January 1995 to November 1999, 79 patients with L-SCLC received combined RT/CT at our Institution. RT was delivered
concurrently or sequentially following the CT. Patients with treatment response received additional prophylactic cranial irradiation
(PCI).
Results Of the patients treated, 54% had received concurrent CT/RT compared to 46% receiving RT following the CT. PCI was administered
to 80% of the patients. Complete response was observed in 66% of patients. With a median follow up of 30 months, median overall
survival was 15.9 months; 14.3 months for patients who received RT following CT and 21.6 months for those receiving concurrent
CT/RT. The type of schedule of combined radiochemotherapy was an independent prognostic factor for survival free of local
recurrence, as was additional PCI for distant metastasis-free survival.
Conclusions Our results are similar to those reported previously in the literature. The main point of interest is that our patients were
non-selected. We strongly support the use of concurrent CT/RT so as to achieve results comparable to the best in the literature.
相似文献
997.
María Velasco Latrás Luis Carreras Coderch Fernando Antoñanzas Villar Juan Coya Viña José Martín Comín Francisco Martínez Carderón José Nieto Martín-Bejarano Alberto Sáenz Cusí Gala Serrano Bermúdez Amaya Echevarría Icaza 《Clinical & translational oncology》2005,7(5):198-204
Objective. To evaluate the cost-effectiveness of samarium [153Sm-EDTMP] (Quadramet®) compared to conventional therapy in the treatment of pain in patients with prostate cancer and bone metastases. Method. A decision tree model for the treatment of bone pain due to metastases was adapted to the Spanish context. The model represents the standard treatment patterns in Spain for the study population. The time-course of the model is 4 months and it computes an estimate for the cost of pain control per patient. The effectiveness data for the model derive from a randomised trial. The current treatment patterns have been established according to the consensus opinions of a group of medical experts. Results. The cost of pain control per patient is ? 12,515.39 for conventional therapy and ? 5,595.52 for samarium-153 (Quadramet®) therapy. The incremental cost-effectiveness analysis shows that samarium-153 (Quadramet®) is a dominant therapy. It presents lower costs and higher efficacy than the conventional strategy. The sensitivity analyses showed these results to be robust. Conclusion. Samarium-153 (Quadramet®) is costeffective in treating pain in patients with prostate cancer and bone metastases. 相似文献
998.
The diagnostic usefulness of sentinel lymph node biopsy (SLNB) has been well established, but its therapeutic value remains
unproven. First introduced by Morton and colleagues, the SLNB procedure is now widely available, and markedly enhances our
ability to pathologically stage the regional nodes.
Although the SLN status is acknowledged as the most powerful indicator of prognosis in melanoma, there is no evidence to-date,
of survival advantage for complete lymphadenectomy in SLN-positive patients. Also, there is no effective adjuvant therapy
that could benefit these sentinel node-positive patients, as yet. Additionally, new data have emerged indicating a possible
increase in local/in-transit recurrence following complete lymphadenectomy in sentinel node-positive patients. To understand
fully and to evaluate these observations we need information from randomized controlled trials.
Major changes have occurred following the latest revision of melanoma staging system (AJCC, 6th edition). Concerning N category,
these include the incorporation of the number of metastatic lymph nodes, the tumour burden of nodal metastases, and the ulceration
of the primary tumour. The data obtained from the new staging system will reflect differences in prognosis that were not previously
emphasized and which, we hope, will serve as a guide to more accurate analysis of metastatic pathways in cutaneous melanoma
as well as a rationale for new forms of treatment. 相似文献
999.
1000.
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. 总被引:15,自引:0,他引:15
Daphne W Bell Thomas J Lynch Sara M Haserlat Patricia L Harris Ross A Okimoto Brian W Brannigan Dennis C Sgroi Beth Muir Markus J Riemenschneider Renee Bailey Iacona Annetta D Krebs David H Johnson Giuseppe Giaccone Roy S Herbst Christian Manegold Masahiro Fukuoka Mark G Kris José Baselga Judith S Ochs Daniel A Haber 《Journal of clinical oncology》2005,23(31):8081-8092
PURPOSE: Most cases of non-small-cell lung cancer (NSCLC) with dramatic responses to gefitinib have specific activating mutations in the epidermal growth factor receptor (EGFR), but the predictive value of these mutations has not been defined in large clinical trials. The goal of this study was to determine the contribution of molecular alterations in EGFR to response and survival within the phase II (IDEAL) and phase III (INTACT) trials of gefitinib. PATIENTS AND METHODS: We analyzed the frequency of EGFR mutations in lung cancer specimens from both the IDEAL and INTACT trials and compared it with EGFR gene amplification, another genetic abnormality in NSCLC. RESULTS: EGFR mutations correlated with previously identified clinical features of gefitinib response, including adenocarcinoma histology, absence of smoking history, female sex, and Asian ethnicity. No such association was seen in patients whose tumors had EGFR amplification, suggesting that these molecular markers identify different biologic subsets of NSCLC. In the IDEAL trials, responses to gefitinib were seen in six of 13 tumors (46%) with an EGFR mutation, two of seven tumors (29%) with amplification, and five of 56 tumors (9%) with neither mutation nor amplification (P = .001 for either EGFR mutation or amplification v neither abnormality). Analysis of the INTACT trials did not show a statistically significant difference in response to gefitinib plus chemotherapy according to EGFR genotype. CONCLUSION: EGFR mutations and, to a lesser extent, amplification appear to identify distinct subsets of NSCLC with an increased response to gefitinib. The combination of gefitinib with chemotherapy does not improve survival in patients with these molecular markers. 相似文献